Skip to content

Bristol-Myers Squibb

US · BMY #122 by market cap Listed 1970 -1.14%
61.54 -0.71 -1.14%
Live - 304 symbols - heartbeat 32s ago · 2026-09-23 14:20
Pre-market 62.12 -0.21%
After-hours 62.30 +0.08%
Overnight 62.45 +0.32%
Market cap
125.71B
P/B
5.63
EPS
3.46
Reader sentiment Are you bullish or bearish on BMY?

Anonymous reader poll. Unscientific, not investment advice.

Bristol-Myers Squibb ended the session at 61.54, down 1.14%. The company carries a market value of roughly 125.71B, the #122 most valuable US-listed company we track. Valuation-wise, the P/E sits at 14.01, 59% above the five-year average of 8.81. It pays a dividend yielding 4.08% on a trailing basis. Wall Street's 18-analyst consensus lands on Buy, with a price target averaging 67.88 (+10% from here). Against a 52-week band of 41.13-68.64, the shares are currently 74% of the way up.

StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +28.7% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 2.2% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 299 U.S. stocks StockVane covers.

Overall B
Valuation A-

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 13.6x Better than 84%
Forward P/E 16.0x Better than 66%
Price / Sales 2.6x Better than 71%
P/E vs own 5-yr range 38th pctl Better than 73%
Growth C-

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 1.4% Better than 22%
Net income CAGR (3Y) 3.7% Better than 38%
Free cash flow CAGR (3Y) 2.4% Better than 36%
Profitability B+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 71.1% Better than 82%
Operating margin 28.5% Better than 68%
Net margin 14.6% Better than 43%
Return on equity 40.5% Better than 79%
Return on invested capital 12.7% Better than 51%
Momentum B+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 13.9% Better than 76%
6-month return 7.4% Better than 45%
12-month return (ex latest month) 57.0% Better than 81%
Distance below 52-week high 10.0% Better than 62%
Financial Health C+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 1.3x Better than 51%
Debt to assets 255.2% Better than 10%
Interest coverage 5.9x Better than 31%
Free cash flow / net income 182.1% Better than 86%
Analyst View D+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 44.4% Better than 13%
Upside to average target 9.9% Better than 22%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice.

Price chart

68.0953.4061.932026-03-252026-09-23
MA5MA10MA20MA60
MA5 MA10 MA20 MA60

Performance

1W -2.63%
1M -7.58%
3M +12.78%
6M +11.01%
YTD +18.69%
1Y +44.52%
3Y +21.09%
5Y +25.36%

Key statistics

Price & volume

Prev close
62.25
Open
62.36
Day range
61.45 - 62.65
Avg price
61.79
Volume
4.59M
Turnover
283.33M
Amplitude
1.93%
52-week range
41.13 - 68.64

Valuation

P/E
17.79
P/E (TTM)
13.56
P/B
5.63
EPS
3.46
Net profit
7.07B
Net assets
22.32B

Share structure

Market cap
125.71B
Float cap
125.51B
Shares out
2.04B

Dividend & listing

Dividend (TTM)
2.51
Listing date
1970-01-01
52-week range 74% of range
41.13 68.64

10.3% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-81.67M net over the window

Short interest

Shares short
44.07M
As of
2026-08-31

Frequently asked questions

What is the current stock price of Bristol-Myers Squibb (BMY)?

Bristol-Myers Squibb last traded at 61.54. The quote on this page refreshes every few seconds while US markets are open.

What is Bristol-Myers Squibb's market cap?

About 125.71B.

What is the P/E ratio of Bristol-Myers Squibb?

The trailing twelve-month P/E is 13.56, above its own 5-year average of 8.81 — in the middle of its historical range (37.56% percentile). See the Valuation tab for the full history.

Does Bristol-Myers Squibb pay a dividend?

Yes. The trailing dividend yield is 4.08%. See the Dividends tab for the full payment history.

Is Bristol-Myers Squibb a buy according to analysts?

The consensus of 18 analysts is a Buy rating, with an average 12-month price target of 67.88, which implies 10.3% upside from the current price. This is not investment advice.

Quote time 2026-09-23 14:20:00 · For reference only, not investment advice.